deltatrials
Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06214156

A Clinical Study of T3011 in Subjects With Advanced Melanoma

A Phase Ib/IIa Clinical Study to Evaluate the Tolerability, Safety and Preliminary Efficacy of T3011 in Subjects With Advanced Melanoma

Sponsor: Shanghai Pharmaceuticals Holding Co., Ltd

Conditions Advanced Melanoma
Interventions T3011
Updated 8 times since 2024 Last updated: Jan 12, 2026 Started: Jan 26, 2024 Primary completion: Sep 30, 2026 Completion: Sep 30, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Advanced Melanoma, this trial is actively recruiting participants. The trial is conducted by Shanghai Pharmaceuticals Holding Co., Ltd and has accumulated 8 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2024 – ~Mar 2024 · 29 days · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshotRecruiting~Jan 2025 – ~May 2025 · 4 months · monthly snapshotRecruiting~May 2025 – ~Feb 2026 · 9 months · monthly snapshotRecruiting~Feb 2026 – present · 4 months · monthly snapshotRecruiting

Change History

8 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE1/PHASE2

  2. May 2025 — Feb 2026 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jan 2025 — May 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Sep 2024 — Jan 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 3 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  2. Mar 2024 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Feb 2024 — Mar 2024 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Jan 2024

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shanghai Pharmaceuticals Holding Co., Ltd
Data source: Shanghai Pharmaceuticals Holding Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations